Android app on Google Play

Opko Health (OPK) Buy Maintained at Jefferies Post Call

December 18, 2013 6:56 AM EST Send to a Friend
Get Alerts OPK Hot Sheet
Price: $8.81 -0.11%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 13 | New: 4
Trade OPK Now!
Join SI Premium – FREE
Jefferies analyst Eun Yang reiterated a Buy rating and $11.50 price target on Opko Health (NYSE: OPK) following the company's conference call addressing negative short seller reports highlighting its late-stage diagnostic/pharmaceutical program.

"In our view, timely achievements of its laid-out milestones and future sales revenues meeting our expectations (albeit significantly lower than its noted market opportunities) would likely provide potential upside to current levels," the analyst said.

On diagnostics for prostate cancer, OPK expects clinical validation data for
4Kscore (n=1,200) & U.S. launch via its CLIA-certified lab in ~1Q14; for Claros-1
platform, it plans to restart clinical trials for Total-PSA in 1Q14.

On late-stage pharmaceuticals, Ph3 data for TSRO-partnered rolapitant is
expected by YE13/early-2014, Rayaldy in ~mid-2014 and hGH-CTP in 2015, with
potential launches in 2015-2017.

For an analyst ratings summary and ratings history on Opko Health click here. For more ratings news on Opko Health click here.

Shares of Opko Health closed at $8.40 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment